News

Date	Description
07/07/10	Synageva BioPharma Receives Orphan Drug Designation for SBC-102 for Lysosomal Acid Lipase Deficiency

05/04/10	Synageva BioPharma Files for Orphan Drug Designation for SBC-102, Being Developed to be the First Enzyme Replacement Therapy to Treat Lysosomal Acid Lipase Deficiency - A Progressive, Often Fatal Disease

10/20/2009	Synageva BioPharma Announces Completion of $45 Million Financing With New $12 Million Investment, Addition of New Leaf Venture Partners to Investor Group, and Expansion of Senior Leadership Team

07/01/2009	Morphotek®, Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

05/05/2009	Synageva Biopharma Adds Two New Investors and Announces Additional Funding

04/15/2009	Synageva Biopharma Announces $30 Million Equity Financing

10/09/2008	Synageva Biopharma appoints Leading Clinician and Industry Executive, Dr. Mark Goldberg, to its Board of Directors.

09/01/2008	Synageva Biopharma appoints Sanj K. Patel president and chief executive officer and opens new corporate headquarters